Mechanism of action<unk>  is a serotonin receptor agonist that, like the unsuccessful LY-334,370, selectively binds to the 5-HT1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT1B and 5-HT1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible people, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction, although a 1998 review has found such side-effects to rarely occur in people taking triptans.
Lasmiditan
Dietitian
Serenic
Gutter oil
Riken
Pedestrian
Balm in Gilead 
Cochrane 